You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202201 - 202210 of 204843 results
  1. IMAGING OF APOPTOSIS

    SBC: MOLECULAR THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to continue development of a novel molecular imaging reporter construct that can report induction of apoptosis in intact cells and animals. Under normal biological conditions a tight balance between proliferation and cell death (apoptosis) is essential. An imbalance in these two opposing processes has been implicated in a va ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Thermal Management Materials Technologies for High Power Naval Systems

    SBC: BNNT LLC            Topic: N181078

    Heat dissipation requirements have become the critical limiter of performance, efficiency, lifetime, and lifecycle costs as performance demands on electronics increase. This is especially a challenge in naval systems, including phased-array radar, smart weapons, electronic countermeasures (ECM), directed energy weapons, and electronics counter-countermeasures (ECCM). High performance passive cooli ...

    SBIR Phase II 2019 Department of DefenseNavy
  3. Reading workstation for clinical contrast echocardiography

    SBC: Narnar, LLC            Topic: NHLBI

    PROJECT SUMMARY Coronary microvascular dysfunction (MVD) is increasingly being appreciated as a part of the pathophysiology of a number of conditions including MINOCA (myocardial infarction with nonobstructive coronary arteries), heart transplant graft vasculopathy, and heart failure with preserved ejection fraction (HFpEF). Coronary MVD occurs more commonly in women and can result in chest pain d ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. All Terrain Combat Identification

    SBC: Spectra Research, Inc.            Topic: A03097

    Spectra Research and the Georgia Tech Research Institute (GTRI) are proposing to develop, demonstrate, and deliver compact ultra-broadband omni-directional non-transponder RF Tags employing both current (Spectra Research) design topologies (with separate dielectric antennas for each radar interrogation band) and the latest designs employing an innovative fragmented aperture antenna to cover all ba ...

    SBIR Phase II 2004 Department of DefenseArmy
  5. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 12% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS increased from $9B to $64B, with a corresponding rise in surgical treatment for those 20% o ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. PERCUTANEOUS TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE WITH IMPLANTATION OF MULTIPLE, BALLOON-EXPANDABLE, DRUG-ELUTING BIORESORBABLE SCAFFOLDS (the Efemoral Vascular Scaffold System)

    SBC: Efemoral Medical, LLC            Topic: NHLBI

    Cardiovascular disease is a tremendous burden on human health and longevity; by the year 2030, over 400million people will have the disease including an annual mortality of more than 23 million. Vascular diseaseaffecting the lower extremity arteries, known as “peripheral arterial occlusive disease” (PAOD), is an epidemicaffecting approximately 10% of the population over the age of 50 and 20% o ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Neuro-Optical Diagnostic System for Macular Degeneration

    SBC: NEUROFIELDZ INC.            Topic: NIA

    NeuroFieldz is pursuing commercialization of NeuroDotVR, a portable wireless diagnostic system for neuro- visual disorders. The company is currently working on a Phase II SBIR project on early diagnostics for Macular Degeneration. NeuroFieldz has developed a carefully conceived commercialization plan to translate the NeuroDotVR technology to the marketplace. NeuroFieldz was recently the subject of ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)

    SBC: CARTESIAN THERAPEUTICS INC            Topic: NCI

    ABSTRACT Multiple myeloma (MM) claims over 80,000 lives globally each year. Although several new therapies have been approved over the past decade, virtually all patients relapse, and the median survival remains at only 5 years. The depth of therapeutic response correlates with time to relapse, and eradicating tumor cells early in the disease process may be necessary to achieve clinical cure. A po ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: N/A

    DESCRIPTION (provided by applicant): HIV-associated adipose redistribution syndrome (HARS), a form of lipodystrophy, is a common problem in HIV patients on highly active antiretroviral therapy and occurs as a side-effect of their anti-viral drug therapies. HARS is characterized by an increase in visceral adipose tissue, dyslipidemia, and insulin insensitivity, all of which are believed to increas ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer

    SBC: Stemsynergy Therapeutic            Topic: NCI

    ABSTRACT The incidence of esophageal adenocarcinoma (EAC) has tripled over the last 40 years, but five-year overall survival is still poor due to late stage diagnosis, metastasis, and high rates of recurrence after standard chemotherapy. Standard-of-care therapy (neoadjuvant chemotherapy, radiation, or both followed by esophagectomy) achieves only 20% response rates, while 80% of patients remain p ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government